A PD-L1-positive expression was associated with a higher T stage (p = 0.049), higher proportion of patients receiving palliative immunotherapy (23.5% vs. 2.4%, p = 0.007), and lower proportion of patients exhibiting bladder tumour recurrence after an operation during follow-up (0% vs. 28.2%, p = 0.01). The gene discussed is CD274; the disease is urinary bladder neoplasm.